Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, No. 324, Jingwu Road, Jinan, 250021, Shandong, People's Republic of China.
School of Medicine, Shandong University, Jinan, 250012, Shandong, China.
J Cancer Res Clin Oncol. 2019 Oct;145(10):2413-2422. doi: 10.1007/s00432-019-02994-0. Epub 2019 Sep 6.
Polo-like kinase 4 (PLK4) is a serine/threonine protein kinase that regulates centriole duplication. PLK4 deregulation causes centrosome number abnormalities, mitotic defects, chromosomal instability and, consequently, tumorigenesis. Therefore, PLK4 has emerged as a therapeutic target for the treatment of multiple cancers. In this review, we summarize the critical role of centrosome amplification and PLK4 in cancer. We also highlight recent advances in the development of PLK4 inhibitors and discuss potential combination therapies for cancer.
The relevant literature from PubMed is reviewed in this article. The ClinicalTrials.gov database was searched for clinical trials related to the specific topic.
PLK4 is aberrantly expressed in multiple cancers and has prognostic value. Targeting PLK4 with inhibitors suppresses tumor growth in vitro and in vivo.
PLK4 plays an important role in centrosome amplification and tumor progression. PLK4 inhibitors used alone or in combination with other drugs have shown significant anticancer efficacy, suggesting a potential therapeutic strategy for cancer. The results of relevant clinical trials await evaluation.
Polo 样激酶 4（PLK4）是一种丝氨酸/苏氨酸蛋白激酶，可调节中心体复制。PLK4 失调会导致中心体数量异常、有丝分裂缺陷、染色体不稳定，进而导致肿瘤发生。因此，PLK4 已成为治疗多种癌症的治疗靶点。在这篇综述中，我们总结了中心体扩增和 PLK4 在癌症中的关键作用。我们还强调了 PLK4 抑制剂开发的最新进展，并讨论了癌症的潜在联合治疗策略。
本文综述了来自 PubMed 的相关文献。在 ClinicalTrials.gov 数据库中搜索了与特定主题相关的临床试验。
PLK4 在多种癌症中异常表达，具有预后价值。用抑制剂靶向 PLK4 可抑制体外和体内肿瘤生长。
PLK4 在中心体扩增和肿瘤进展中起重要作用。PLK4 抑制剂单独或与其他药物联合使用已显示出显著的抗癌疗效，提示这是一种有潜力的癌症治疗策略。相关临床试验的结果有待评估。
